Skip to content

The use of SPEctroscopy during Endoscopy for Detection of PANcreatic Cancer

The use of SPEctroscopy during Endoscopy for Detection of PANcreatic Cancer - SPEEDPANC

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON50186
Enrollment
45
Registered
2018-06-22
Start date
2019-03-07
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreas pancreatic cancer pancreatic lesions

Interventions

None listed

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients scheduled for EUS-FNA, due to a suspect lesion of the pancreas

Exclusion criteria

Exclusion criteria: - Patients with age under 18 years - Patients who object to participate in this study.

Design outcomes

Primary

MeasureTime frame
The shape of the spectra and the optical absorption coefficients over a broad wavelength range will be used to distinguish pancreatic tumors and benign pancreatic tissue. To extract and quantify physiological information from the obtained spectra, such as blood volume fraction and tissue oxygenation, a validated mathematical model, based on the knowledge of the absorption spectra of the chromophores, will be used. Therefore, we need to determine the serum bilirubin and hemoglobin, before the EUS-FNA is performed, which is part of the clinical workflow ('zorgpad pancreas'). The obtained spectra will be linked to final cytological analysis.

Secondary

MeasureTime frame
The diagnostic accuracy (including sensitivity, specificity, negative predictive value and positive predictive value) of one or more combined wavelengths specific for pancreatic tumor tissue will be calculated after comparison to cytological and final diagnosis.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)